<DOC>
	<DOC>NCT01628692</DOC>
	<brief_summary>The purpose of this study is to assess the safety and efficacy of daclatasvir and simeprevir with and without ribavirin for genotype 1 chronic hepatitis C virus infection in patients who are treatment-naive or null responders to previous pegylated interferon/ribavirin therapy.</brief_summary>
	<brief_title>Study of Daclatasvir (BMS-790052) and Simeprevir (TMC435) in Patients With Genotype 1 Chronic Hepatitis C Virus</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Simeprevir</mesh_term>
	<criteria>Key Hepatitis C virus (HCV) genotype 1a or 1b Males and females, ≥18 years of age HCV RNA ≥10,000 IU/mL Participants with compensated cirrhosis are permitted Advanced fibrosis (F3/F4) is capped at approximately 35% of the total treated population with a minimum of 20% F4 patients If no cirrhosis, a liver biopsy within 3 years prior to enrollment If cirrhosis is present, any prior liver biopsy Key Liver or any other transplant (other than cornea and hair) Evidence of a medical condition contributing to chronic liver disease other than HCV infection Current or known history of cancer, (except in situ carcinoma of the cervix or adequately treated basal or squamous cell carcinoma of the skin) within 5 years prior to enrollment Evidence of decompensated liver disease including, but not limited to, radiologic criteria, a history or presence of ascites, bleeding varices, or hepatic encephalopathy Patients infected with HIV or hepatitis B virus Gastrointestinal disease impacting absorption of study drug Uncontrolled diabetes or hypertension Prior exposure to an HCV directacting agent Any criteria that would exclude the patient from receiving ribavirin Absolute neutrophil count &lt;1.5*1,000,000,000 cells/L (&lt;1.2*1,000,000,000 cells/L for Black/African Americans) Platelets &lt;90*1,000,000,000 cells/L Hemoglobin &lt;12 g/dL for females, &lt;13 g/dL for males Alanine aminotransferase ≥5*upper limit of normal In patients without cirrhosis, total bilirubin ≥2 mg/dL unless patient has a documented history of Gilbert's disease In patients with cirrhosis, total bilirubin o ≥1.5 mg/dL International normalized ratio ≥1.7 QTcF or QTcB &gt;500 mSec Creatinine clearance ≤50 mL/min Alpha fetoprotein (AFP) &gt;100 ng/mL OR AFP ≥50 ng/mL and ≤100 ng/mL requiring liver ultrasound Albumin &lt;3.5 g/dL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>